Cristina Nanni, MD. a leader in prostate cancer nuclear imaging, presents the data on Flucicovine F18 (FACBC), a new radiopharmaceutical and its application in diagnosisng biochemical replapse in post prostatectomy patients based upon a rising PSA.  Dr. Nanni also presents details on its mechanism of action in prostate cancer cells, the current clinical approach and reviews of patient case studies based on direct experiences in the devlopment of Flucicovine F18 (FACBC) . The discussion concludes with Dr. Phillip Koo leading a brief question and answer session on the practical applications of  Flucicovine F18. 


For More information of the use of F18 in the diagnosis of recurrent prostate cancer:


SNMMI 2016: Fluciclovine F18 (FACBC): An Amino Acid Tracer for the Staging of Recurrence Prostate Cancer

FDA Approval of Axumin™ (Flucicovine F18 (FACBC)

18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse: A Comparison to 11C-Choline PET/CT.


Biography:

Cristina Nanni, MD.
Dr. Cristina Nanni is a Nuclear Medicine Physician working at the PET Centre in Bologna (ITALY) since 2007.

She got her residency in Nuclear Medicine at the University  Bologna (2000 to 2004) and in Radiology in 2012. She worked in the field of pre-clinical PET imaging in 2005 and 2006. Now she is responsible for new radiotracers applications and integration of morphological and functional imaging (PET/ceCT and PET/CT guided biopsy) in the clinical practice. 
Recently she is been working on the application of FACBC as an alternative tracer beside Choline in prostate cancer patients.
She is author and co-author of 190 clinical and pre-clinical papers published in international journals and more than 200 abstracts presented at national and international congresses as posters and oral presentations.

Phillip Koo, MD